Roche lupus drug Gazyva gets FDA filing acceptance
Roche (OTCQX: RHHBY) said the FDA accepted its supplemental BLA for Gazyva/Gazyvaro (obinutuzumab)…
Roche’s Gazyva wins EU nod for adults with active lupus nephritis
Roche (RHHBY) announced that the European Commission approved Gazyva/Gazyvaro (obinutuzumab) on 9 December 2025 for adults with active…
Roche lupus drug cuts disease activity in phase III
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly…
How Investors Are Reacting To Roche Holding (SWX:ROG) FDA Approval and Breakthrough Clinical Trial Results
Roche announced a series of major product milestones, including FDA approval for Gazyva in lupus nephritis and positive…
Roche’s Gazyva Meets Phase III SLE Endpoints at 52 Weeks
Roche (RHHBY) announced on 3 November 2025 that the phase III ALLEGORY study…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
F. Hoffmann-La Roche Ltd Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Gazyva Data Reshapes Roche Kidney Disease Story As Regulatory Calls Near
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…
Roche eyes Gazyva label expansion on positive Phase III kidney disease data
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during…
Roche Gazyva phase III remission win in kidney disease
Roche (OTCQX:RHHBY) announced that the phase III MAJESTY study in adults with primary…
Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease
F. Hoffmann-La Roche Ltd MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary…